Tus-Pharmaceutical Group Co., Ltd.

000590

CNE000000701

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-06-11 EDT			5-day change	1st Jan Change
5.79 ^CNY	+3.02%		-1.36%	-35.38%

04-25	Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-27	Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tus-Pharmaceutical Group Co., Ltd. agreed to acquire 55% stake in Wuhan Medtek Pharmaceutical Co., Ltd. from Tan Yunliang and Wang Zhong for approximately CNY 140 million.

January 11, 2024

Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) agreed to acquire 55% stake in Wuhan Medtek Pharmaceutical Co., Ltd. from Tan Yunliang and Wang Zhong for approximately CNY 140 million on January 11, 2024. As of August 2023, Wuhan Medtek Pharmaceutical Co., Ltd. generated total assets of CNY 106.1 million and net assets of CNY 83.9 million. The transaction is approved by board of directors of Tus-Pharmaceutical Group Co., Ltd. and is subject to shareholders approval.

Latest news about Tus-Pharmaceutical Group Co., Ltd.

Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Tus Pharmaceutical to Boost Investment in Chemical Park Project	01-12	MT
Tus-Pharmaceutical Group Co., Ltd. agreed to acquire 55% stake in Wuhan Medtek Pharmaceutical Co., Ltd. from Tan Yunliang and Wang Zhong for approximately CNY 140 million.	01-11	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Tus-Pharmaceutical Group Co., Ltd. Approves Board Appointments	23-05-19	CI
Tus Pharmaceutical to Set Up New Marketing Subsidiary	23-05-18	MT
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Guhan Traditional Chinese Medicine Co., Ltd. announced that it expects to receive CNY 22 million in funding from Tus-Pharmaceutical Group Co., Ltd.	22-12-29	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Tus-Pharmaceutical Group Co., Ltd. completed the acquisition of Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang.	22-08-23	CI
Tus Pharmaceutical to Buy Local Drugmaker Xiantong for $33 Million	22-08-03	MT
Tus-Pharmaceutical Group Co., Ltd. agreed to acquire 100% stake in Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang fron CNY220 million.	22-08-02	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Hunan Tus-Pharmaceutical Biological Co., Ltd. announced that it expects to receive CNY 25 million in funding from Tus-Pharmaceutical Group Co., Ltd., Ningbo Yiduoduo Electronic Commerce Co., Ltd.	22-01-17	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-29	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-29	CI
Tus Pharmaceutical : Adopts New Name	20-12-22	MT
Tus-Guhan Group Corp.,Ltd. Approves Board Elections	20-12-11	CI
Tus-Guhan Group Corp.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-29	CI

Chart Tus-Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Tus-Pharmaceutical Group Co., Ltd.

More charts

Company Profile

Tus Pharmaceutical Group Co Ltd, formerly Tus-Guhan Group Corp Ltd, is principally engaged in the manufacture and sale of pharmaceuticals. The Company provides Chinese medicines, including Chinese healthcare products, medicines for cold treatment and anti hyperlipemia medicines, among others. It also provides western medicine preparations, including clindamycin phosphate for injection, lomefloxacin hydrochloride for injection and levofloxacin lactate for injection, among others. The Company distributes its products in domestic markets.

Sector

Pharmaceuticals

Calendar

2024-06-28 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TUS-PHARMACEUTICAL GROUP CO., LTD.	-35.38%	186M
ELI LILLY AND COMPANY	+48.79%	780B
NOVO NORDISK A/S	+41.76%	627B
MERCK & CO., INC.	+19.43%	334B
ABBVIE INC.	+7.18%	296B
ASTRAZENECA PLC	+17.60%	244B
ROCHE HOLDING AG	-0.41%	217B
NOVARTIS AG	+11.54%	214B
AMGEN INC.	+4.53%	161B
PFIZER, INC.	-3.92%	159B

Other Pharmaceuticals